← The record

Milk Powder Synthetic, Low Calcium Oral Powder

Recommended MetabolicRestrictedNot applicable line

Dietary management of hypercalcaemia in patients under 4 years of age.

1
Submissions
1 resub
2024–24
On the record
ICER range
Not modelled
Cost basis

Access path

1 submission · public record
  1. Jul 2024
    Recommended
  2. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC recommended that the new formulation of milk powder synthetic low calcium oral powder 400 g (Locasol®) continue to be listed on the PBS under the existing conditions as the current formulation.PSD · Jul 2024
6.2 The PBAC noted and supported the NPWP’s advice that the new formulation is expected to provide non-inferior clinical benefit and safety compared to the current formulation for the dietary management of hypercalcaemia.PSD · Jul 2024

Cost-effectiveness

No economic analysis performed; this is a formulation change submission with no change to price or listing conditions.

Decision context

PopulationInfants and children under 4 years of age requiring dietary management of hypercalcaemia.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Jul 2024 Recommended Other

Similar precedents

By decision profile